We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.72B
1-Year Est. Return
106.92%
This Fund
S&P 500
This Quarter
Est. Return
+23.52%
1 Year Est. Return
+106.92%
3 Year Est. Return
+205.04%
5 Year Est. Return
+179.05%
10 Year Est. Return
+1,028.38%
AUM
$1.72B
AUM Growth
+$488M
(+40%)
Cap. Flow
+$170M
Cap. Flow
% of AUM
9.86%
Top 10 Holdings %
Top 10 Hldgs %
73.48%
Holding
28
New
6
Increased
2
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
COAG
Hemab Therapeutics
COAG
|
+$115M |
| 2 |
AVLN
Avalyn Pharma
AVLN
|
+$112M |
| 3 |
Floor & Decor
FND
|
+$40.3M |
| 4 |
ALMS
Alumis Inc
ALMS
|
+$25.6M |
| 5 |
Dyne Therapeutics
DYN
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APGE
Apogee Therapeutics
APGE
|
+$37.9M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$37.3M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$20.1M |
| 4 |
ArriVent BioPharma
AVBP
|
+$13M |
| 5 |
Enliven Therapeutics
ELVN
|
+$11.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.11% |
| 2 | Technology | 14.96% |
| 3 | Financials | 8.68% |
| 4 | Consumer Discretionary | 4.18% |
| 5 | Industrials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.68B
| $217M | 12.62% |
5,350,000
| – | – |
|
2
ASML
ASML
$659B
| $189M | 10.97% |
94,946
| – | – |
|
|
COAG
3
Hemab Therapeutics
COAG
$2.07B
| $154M | 8.92% |
+4,180,550
| New | +$115M |
|
4
Brookfield
BN
$90B
| $150M | 8.68% |
3,496,245
| – | – |
|
|
MPLT
5
MapLight Therapeutics
MPLT
$639M
| $132M | 7.67% |
3,686,622
| – | – |
|
|
6
Mirum Pharmaceuticals
MIRM
$6.15B
| $132M | 7.65% |
1,125,000
-200,000
| -15% | -$20.1M |
|
|
AVLN
7
Avalyn Pharma
AVLN
$1.66B
| $128M | 7.42% |
+3,883,289
| New | +$112M |
|
8
Salesforce
CRM
$213B
| $61.6M | 3.58% |
393,187
| – | – |
|
|
9
ArriVent BioPharma
AVBP
$1.53B
| $52.1M | 3.03% |
1,500,000
-442,142
| -23% | -$13M |
|
|
10
Enliven Therapeutics
ELVN
$4.35B
| $50.8M | 2.95% |
1,000,000
-280,000
| -22% | -$11.9M |
|
|
CRNX
11
DELISTED
Crinetics Pharmaceuticals
CRNX
| $49.4M | 2.87% |
1,320,000
-230,000
| -15% | -$8.55M |
|
12
Pharvaris
PHVS
$2.47B
| $48.4M | 2.81% |
1,400,000
-350,000
| -20% | -$10.6M |
|
|
13
Floor & Decor
FND
$5.35B
| $47.3M | 2.75% |
+797,000
| New | +$40.3M |
|
14
Vaxcyte
PCVX
$9.1B
| $46.5M | 2.7% |
800,000
-60,000
| -7% | -$3.26M |
|
15
4D Molecular Therapeutics
FDMT
$827M
| $43.2M | 2.51% |
3,249,178
-401,559
| -11% | -$3.91M |
|
16
Viridian Therapeutics
VRDN
$2.6B
| $39.2M | 2.28% |
2,135,000
+135,000
| +7% | +$2.18M |
|
17
Celldex Therapeutics
CLDX
$3.12B
| $38.1M | 2.21% |
1,025,000
-175,000
| -15% | -$5.65M |
|
|
ALMS
18
Alumis Inc
ALMS
$1.44B
| $31M | 1.8% |
+1,100,000
| New | +$25.6M |
|
19
Xenon Pharmaceuticals
XENE
$5.79B
| $29.3M | 1.7% |
485,438
| – | – |
|
20
Alibaba
BABA
$281B
| $24.7M | 1.43% |
257,327
| – | – |
|
|
21
Dyne Therapeutics
DYN
$4.53B
| $21.3M | 1.24% |
+960,394
| New | +$17.9M |
|
|
BBOT
22
BridgeBio Oncology
BBOT
$720M
| $17.1M | 1% |
2,250,000
+64,077
| +3% | +$535K |
|
23
Insmed
INSM
$27.6B
| $12.9M | 0.75% |
+120,723
| New | +$14.6M |
|
24
Marqeta
MQ
$1.73B
| $7.17M | 0.42% |
110,390
| – | – |
|
25
LanzaTech
LNZA
$80.1M
| $1.08M | 0.06% |
158,148
| – | – |
|
Similar funds
SIM
FDCP
HR
GAM
PIMG
AFG
FMLI
FTCM
Novo Holdings A/S's Q2 2026 Portfolio in Review
As of Q2 2026, Novo Holdings A/S held 28 positions worth $1.72B, up 40% from $1.23B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Novo Holdings A/S deployed $170M of net new capital in Q2 2026, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Hemab Therapeutics: 4,180,550 shares worth $154M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $20.1M trimmed.
- Novo Holdings A/S's largest Q2 2026 buy was Hemab Therapeutics: 4,180,550 shares worth $154M.
- Novo Holdings A/S added most to Viridian Therapeutics in Q2 2026, an estimated $2.18M increase.
- Novo Holdings A/S's biggest Q2 2026 reduction was Mirum Pharmaceuticals, cutting an estimated $20.1M.
- Novo Holdings A/S fully exited Apogee Therapeutics in Q2 2026, selling an estimated $37.9M.
- Novo Holdings A/S's ten largest holdings make up 73% of its $1.72B portfolio in Q2 2026.
- Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2026.
- Novo Holdings A/S's portfolio value rose 40% quarter-over-quarter to $1.72B.
Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.